Back to top

Image: Bigstock

BioDelivery Sciences International, Inc.

Read MoreHide Full Article

BioDelivery’s earnings in the first quarter of 2017 surpassed estimates with revenue beating the same. The company expects sales of its key drug Bunavail to benefit from new contract wins. Since this July, the company has secured improved positioning in six new managed care contracts providing preferred access to Bunavail, which is expected to boost the drug’s sales and profitability in 2017. Moreover, its second marketed drug Belbuca’s sales hit all-time high since the product was launched a year ago. However, the company recently discontinued development of clonidine topical gel for management of painful diabetic neuropathy. BioDelivery’s portfolio as well as its pipeline candidates may also face an intense competition as it targets a highly genericized and crowded market. Its share significantly outperformed the Zacks classified Medical-Biomed/Genetics market so far this year.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioDelivery Sciences International, Inc. (BDSI) - free report >>